(603669)"Lionco Pharmaceutical Group Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603669 · · 13 pages · Chinese
Summary by 6ix AI
The report includes significant financial metrics such as total revenue and net profit for the quarter and year-to-date periods. The financial statements included in the report are unaudited, and the company assures the accuracy and completeness of the information presented.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Lionco Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Lionco Pharmaceutical
- (603669)"Lionco Pharmaceutical Group Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share Changes
- Announcement on Obtaining Drug Registration Certificate for Isavuconazonium Sulfate for Injection by Wholly-owned Subsidiary
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Resolutions of the 12th Meeting of the 5th Board of Directors
- Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
Later from Lionco Pharmaceutical
- (603669)"Lionco Pharmaceutical Group Co., Ltd."First Indicative Announcement on Redemption at Maturity and Delisting of "Lionco Convertible Bonds"
- (603669)"Lionco Pharmaceutical Group Co., Ltd."Second Indicative Announcement on Redemption at Maturity and Delisting of "Lionco Convertible Bonds"
- (603669)"Lionco Pharmaceutical Group Co., Ltd."Third Indicative Announcement on Redemption at Maturity and Delisting of "Lionco Convertible Bonds"
Follow Lionco Pharmaceutical into a list and get an email when it puts out news.
Follow Lionco Pharmaceutical